TGen-HonorHealth Clinical Trial Shows Tumor Shrinkage in 71 Percent of Patients With Late-Stage Pancreatic Cancer
October 03, 2019
October 03, 2019
SCOTTSDALE, Arizona, Oct. 3 -- The Entertainment Industry Foundation's Stand Up To Cancer issued the following news release:
Adding a drug that targets a molecular vulnerability in pancreatic cancer could provide substantial benefit to patients, according to a clinical trial study by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, in conjunction with the Pancreatic Cancer Research Team and Cancer Research And . . .
Adding a drug that targets a molecular vulnerability in pancreatic cancer could provide substantial benefit to patients, according to a clinical trial study by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, in conjunction with the Pancreatic Cancer Research Team and Cancer Research And . . .